Project Grant R01AR085149
- The University of Massachusetts Medical School was awarded a $1,066,302 project grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant will fund the creation of a biomedical knowledgebase to promote and facilitate the use of the Osteoarthritis Initiative (OAI), one of the most extensive osteoarthritis research cohorts. The knowledgebase will...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is supporting the development of an intraarticular (injectable) Wnt inhibitor therapy for the treatment of osteoarthritis (OA). OA is a common and debilitating joint disease affecting nearly 21 million people in the U.S. The $314,363 award, made on September 16, 2025, will fund the...
- This federal Project Grant award of $1,950,412.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), to Wake Forest University Health Sciences. The funding supports research to define how the IRE1A-XBP1-NUPR1 signaling axis in immune cells and chondrocytes contributes to synovial inflammation, cartilage damage, and osteoarthritis pain. The...
- The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant of $413,655 on August 1, 2025 to Arizona State University (ASU) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to develop biomaterials with temporal control of proteins, such as Bone Morphogenetic Proteins (BMPs), to enhance bone repair. The research aims to mimic natural extracellular matrix interactions and synergies...
- This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
- The University of Southern California (USC) received a $628,174 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The purpose of this multi-year grant, with an ultimate completion date of March 31, 2030, is to support research into the cellular origins and molecular mechanisms underlying the development of arthrofibrosis, a debilitating...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $2,070,827 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) to the Icahn School of Medicine at Mount Sinai. This grant aims to identify novel microbial factors that can enhance wound repair, a significant public health issue with over 100 million new acute skin wounds annually and substantial treatment costs exceeding $25 billion. The...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $378,228 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Washington University located in Missouri, USA. The funding supports a 2-year research project to validate a novel pre-clinical rabbit model for studying the progression of hip pre-osteoarthritis (OA) to full-blown OA. The project aims to confirm the rabbit model accurately mimics the...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), is intended to elucidate the effects of blood and blood-derived components on meniscus tissue homeostasis, repair, and post-traumatic osteoarthritis development. The $487,652 award to Duke University will fund research to investigate the mechanisms by which blood-derived immune...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $703,634 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Regents of the University of California, San Francisco (UCSF). The grant, awarded on August 15, 2025, will fund a study to develop and validate age-relative measures of biochemical intervertebral disc health. The research aims to discover the age-course of biochemical disc composition,...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $2,017,972 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Washington University in Missouri. The grant, with a performance period from September 10, 2025 to August 31, 2028, will fund research on the safety and efficacy of intra-articular corticosteroid injections for treating symptomatic osteoarthritis. Key objectives include investigating the effects of injection dose, frequency, and timing on patient outcomes and safety. The research will provide much-needed evidence to guide best practices for this common outpatient procedure and help inform clinical guidelines for osteoarthritis management.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.0m | 9/10/25 |